BBVA USA’s Moderna MRNA Stock Holding History

BBVA USA’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$436K	Sell	1,132 -1,099	-49%	-$405K	0.03%	351
2021 Q2	$524K	Buy	+2,231	New	+$399K	0.03%	340

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

BBVA USA's MRNA Position: Q3 2021 in Review

BBVA USA reduced its Moderna (MRNA) stake by 49% in Q3 2021, selling an estimated $405K and leaving 1,132 shares worth $436K. The position accounts for 0.03% of the portfolio, ranked #351.

BBVA USA first reported a position in MRNA in Q2 2021 and has held it in 2 quarters since. The position peaked at $524K in Q2 2021. 1,140 funds tracked by Wall St. Rank hold MRNA as of Q3 2021.

BBVA USA held 1,132 shares of Moderna worth $436K as of Q3 2021.
BBVA USA sold 1,099 Moderna shares in Q3 2021, an estimated $405K.
Moderna made up 0.03% of BBVA USA's portfolio in Q3 2021, its #351 holding.
BBVA USA first reported a position in Moderna in Q2 2021 and has held it in 2 quarters since.
BBVA USA's Moderna position peaked at $524K in Q2 2021.
1,140 funds tracked by Wall St. Rank held Moderna as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.